DHDylan Hansen

Dylan Hansen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Dylan Hansen has a total of 99 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Predictive Accuracy of Serum N-Terminal Pro-B-Type Natriuretic Peptide Alone and in Combination with Respiratory Function Tests to Identify Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)

    by Zoe Brown, Dylan Hansen, Laura Ross, Wendy Stevens, Kathleen Morrisroe, Alannah Quinlivan, Maryam Tabesh, Gene-Siew Ngian, Diane Apostolopoulos, Joanne Sahhar, et al.

    Background/Objectives: Pulmonary arterial hypertension (PAH) occurs in >12% of systemic sclerosis (SSc) patients and has a high mortality. Annual screening for all SSc patients is the standard of care and can include spirometry (RFT), serum N-terminal pro-B-type natriuretic peptide (NT-proBNP) and echocardiography (TTE). We sought to evaluate the accuracy of NT-proBNP alone to screen for SSc-PAH. Methods: We defined groups as low, intermediate and high risk of PAH according to RFT, TTE and RHC (right heart catheter) parameters. NT-proBNP thresholds predictive of risk group were defined, and ROC curves were used to evaluate the predictive accuracy of the calculated cut-points to diagnose SSc-PAH within the following 12 months. Results: A total of 820 SSc patients had NT-proBNP recorded 12 months prior to RHC, or if no RHC had been performed, within 12 months of the most recently recorded annual visit. The majority (335, 40.85%) were assigned to low risk of PAH, 189 (23.05%) to intermediate risk and 176 (21.46%) to high risk. NT-proBNP level < 122.9 ng/L defined the low-risk group, 122.9–186.6 ng/L defined the intermediate risk and >186.6 ng/L defined the high risk. NT-proBNP ≥210 ng/L with RFT (the ‘ASIG algorithm’) had the highest predictive accuracy, with sensitivity of 86.75% (77.52–93.19%), specificity of 60.71% (58.52–62.87%), PPV of 8.47% (6.69–10.55%), NPV of 99.09% (98.38–99.55%) and AUC of 0.74 (0.70–0.78). NT-proBNP ≥ 210 ng/L alone had sensitivity of 67.05% (56.21–76.70), specificity of 71.91% (70.03–73.72), PPV of 8.25% (6.34–10.52), NPV of 98.30% (97.57–98.86) and AUC of 0.69 (0.64–0.74). NT-proBNP thresholds associated with the three defined risk groups performed similarly overall. Conclusions: NT-proBNP alone, compared to the ASIG algorithm, had a slight reduction in NPV and AUC to predict PAH within 12 months. When NT-proBNP is ≥210 ng/L, the NPV remains high (98.0%).

  • Top Cited Papers
    Open Access

    Mucocutaneous Disease Activity and Damage Accrual in Systemic Lupus Erythematosus: Analyses From the Asia‐Pacific Lupus Collaboration Longitudinal Cohort Study

    by Amanda M. Saracino, Yanjie Hao, Dylan Hansen, Yi‐Hsing Chen, Alberta Hoi, Vera Golder, Jiacai Cho, Aisha Lateef, Worawit Louthrenoo, Laniyati Hamijoyo, et al.

    Objective: This research article aims to describe the prevalence, associations, and health‐related quality of life (HRQoL) impact of mucocutaneous features of systemic lupus erythematosus (SLE). Methods: Data from the Asia‐Pacific Lupus Collaboration cohort were analyzed (2013–2021). Mucocutaneous activity (MC‐A) items were rash, alopecia, and mucosal ulcers; were defined by the Systemic Lupus Erythematosus Disease Activity Index 2000; and were persistent if present for at least six months. Mucocutaneous damage (MC‐D) items were chronic skin ulceration, scarring alopecia, and skin/panniculum scarring and were defined by the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index. HRQoL was measured by 36‐Item Short Form Health Survey (SF‐36) surveys. Multivariate logistic generalized estimating equation models were used to determine correlates of MC‐A at each visit. Time‐varying covariate survival models were used to determine predictors of MC‐D. Results: During a median of 2.5 (interquartile range 1.0–5.1) years’ follow‐up, 1,499 of 4,102 patients (36.5%) had MC‐A (rash n = 1,055, alopecia n = 731, mucosal ulcers n = 352) and 606 of 3,655 patients (16.6%) had persistent MC‐A. These patients were more likely to record worse mean mental (42.6 vs 44.8; P = 0.014) and physical component (41.1 vs 46.1; P < 0.001) SF‐36 scores. Being White, smoking, serologic activity, vasculitis, myositis, serositis, nephritis, and neurologic/psychiatric features were correlates of MC‐A. Of 3,647 patients, 157 (4.3%) accrued MC‐D (skin/panniculum scarring n = 53, alopecia n = 98, ulceration n = 30). These patients had worse mean physical component (39.8 vs 46.0, P = 0.001) SF‐36 scores and were more likely to be White with persistent MC‐A. Conclusion: All mucocutaneous manifestations were associated with worse HRQoL. MC‐A correlated with serologic and systemic disease activity burden in SLE. Persistent MC‐A was associated with increased risk of MC‐D, emphasizing the importance of early and effective treatment. Both MC‐A and MC‐D were more likely in White patients, suggesting ethnic and environmental impacts. Smoking was a potentially modifiable correlate of MC‐A.


  • Open Access

    Characteristics and Outcomes of Male Participants in a Multicenter Longitudinal Australian Study Cohort

    by Emily Lin, Dylan Hansen, Laura Ross, Gene‐Siew Ngian, Susanna Proudman, Gabor Major, Maryam Tabesh, Mandana Nikpour, Jennifer Walker, Lauren Host, et al.

    Objective: The aim of this study was to determine the differences in demographic, serologic, and clinical characteristics between male and female patients with systemic sclerosis (SSc) in an Australian cohort. Methods: This was a retrospective observational study using data from the Australian Scleroderma Cohort Study. Male patients were compared to female patients using chi‐square test, Wilcoxon rank‐sum test, and Student's t ‐test. Survival analysis from time of diagnosis to all‐cause mortality was presented on Kaplan–Meier curves, and a multivariate Cox proportional hazards model was used to evaluate independent predictors of all‐cause mortality. A subanalysis of patients with incident SSc, defined as disease duration less than four years from onset of first non–Raynaud phenomenon manifestation to recruitment, was performed. Results: Of the 2,033 participants, 299 were male, with a female‐to‐male ratio of 5.8:1. Male patients were more likely to present with diffuse skin involvement (43.7% vs 23.6%, P < 0.001) and ever be positive for digital ulcers, digital pitting, gangrene, and tendon friction rubs as well as myositis and interstitial lung disease. Male patients were more likely to have anti–Scl‐70, anti–Jo‐1, anti‐PM/Scl and anti–RNA polymerase III antibodies compared to female patients. Male patients reported more exposure to silica dust, organic solvents, vinyl chloride, and epoxy resin compared with female patients. In the incident cohort, male patients had statistically significantly higher mortality, with 60% of male patients compared to 82% of female patients surviving 10 years from diagnosis ( P < 0.001). Conclusion: Male patients with SSc have more extractable nuclear antigen antibody positivity and reduced survival in comparison to female patients. The significant difference between occupational exposures recorded between sexes warrants further investigation into the role of industrial exposures in the pathogenesis of SSc in male patients. image

  • Open Access

    The prognostic importance of worsening dyspnoea in systemic sclerosis related interstitial lung disease

    by Kathleen Morrisroe, Dylan Hansen, Wendy Stevens, Laura Ross, Joanne Sahhar, Gene-Siew Ngian, Lauren V Host, Susanna Proudman, Murray Barron, Mandana Nikpour


  • Open Access

    Characterisation and outcomes of different subsets of low disease activity states in patients with systemic lupus erythematosus

    by Yanjie Hao, Dylan Hansen, Worawit Louthrenoo, Yi-Hsing Chen, Jiacai Cho, Aisha Lateef, Laniyati Hamijoyo, Shue-Fen Luo, Yeong-Jian Jan Wu, Sandra Navarra, et al.

    Objectives The lupus low disease activity state (LLDAS) allows for certain clinical and/or serological activity of SLE, provided overall disease activity does not exceed predefined cut-offs. This study aimed to evaluate the outcomes of patients who achieved LLDAS with clinical activity, serological activity only or neither clinical nor serological activity. Methods Patients with SLE enrolled in a prospective multinational cohort from March 2013 to December 2020 who were in LLDAS at least once were included. Visits that fulfilled both LLDAS and Definition of Remission in SLE (DORIS) criteria were excluded. Results 2099 patients were included, with median follow-up of 3.5 (IQR 1.3–5.8) years. At 6150 visits, patients were in LLDAS but not DORIS criteria; of these 1280 (20.8%) had some clinical activity, 3102 (50.4%) visits had serological activity only and 1768 (28.8%) visits had neither clinical nor serological activity. Multivariable regression analysis showed that compared with non-LLDAS, all three subsets of LLDAS had a protective association with flares in the ensuing 6 months and damage accrual in the ensuing 36 months. LLDAS with no clinical or serological activity had a significantly stronger protective association with severe flares in the ensuing 6 months compared with LLDAS with clinical activity (HR 0.47, 95% CI (0.27 to 0.82), p=0.007). Conclusions LLDAS without any clinical activity accounted for almost 80% of LLDAS visits. This study confirms that all subsets of LLDAS are associated with reduced flare and damage accrual. However, LLDAS without any clinical or serological activity has the strongest protective association with severe flares.


  • Observations from Australia’s National Surgical Mortality Audit

    by Dylan Hansen, Franca Itotoh, Kopunic Helena, R. James Aitken, The Australian And New Zealand Audit Of Surgical Mortality

    Background Australia is the only country with a national surgical mortality audit. Every Australian surgical mortality is independently and externally reviewed by another surgeon. Extensive educational feedback to surgeons and hospitals is provided through individual patient reviews, state and national symposia and reports, and the distribution of deidentified informative cases. This study reports a longitudinal analysis of the Australian surgical morality audit. Methods The standardised mortality ratio (SMR) was calculated for each state and territory, nine surgical specialties and nationally. The index year used was 2016, or every 5 years for those states with earlier data. Overall data were analysed in three groups—all deaths, postoperative deaths and non-operative deaths. Overall specialty data were analysed nationally. Results There was a consistent progressive fall, usually in excess of 20%, in the SMR in each state and territory and by specialty when compared to the index year. This was statistically significant nationally (p = 0.044). The same change was observed in earlier years in states with longer-term data. Conclusion The period of this observational study has been associated with a nationwide fall in surgical mortality. As other improvements in care will have occurred during this period, the contribution that Australia’s national mortality audit made towards the lower surgical mortality cannot be stated with certainty.


  • Open Access

    Gastric antral vascular ectasia in systemic sclerosis: a study of its epidemiology, disease characteristics and impact on survival

    by Kathleen Morrisroe, Dylan Hansen, Wendy Stevens, Joanne Sahhar, Gene-Siew Ngian, Catherine Hill, Janet Roddy, Jennifer Walker, Susanna Proudman, Mandana Nikpour

    Background: To describe the epidemiology, determinants and survival impact of gastric antral vascular ectasia (GAVE) in systemic sclerosis (SSc). Methods: Consecutive SSc patients prospectively enrolled in the Australian Scleroderma Cohort Study (ASCS) were included. Univariable and multivariable logistic regression were used to determine the associations of GAVE with clinical manifestations and serological parameters. Kaplan-Meier (K-M) survival curves were used to estimate survival. Results: The prevalence of GAVE in this SSc cohort of 2039 SSc patients was 10.6% (n = 216) over a median follow-up period of 4.3(1.7–8.4) years. SSc patients with a history of GAVE compared with those without a history of GAVE were older at SSc onset [49.5 (40.0–58.2) vs 46.7 (36.0–56.7) years, p = 0.05]; more likely to have diffuse disease subtype (dcSSc) (35.3% vs 24.1%, p < 0.001); be negative for Scl-70, U1RNP and Scl/PM antibody (4.0% vs 16.1%, p < 0.001, 3.5% vs 7.4%, p = 0.041, 0.0% vs 2.0%, p = 0.042; and respectively) and positive for RNAP III antibody (24.9% vs 8.3%, p < 0.001). Those with GAVE had a worse HRQoL (p = 0.002). Independent determinants of GAVE included the presence of RNAP III antibody (OR 3.46, p < 0.001), absence of Scl-70 antibody (OR 0.23, p = 0.001), presence of GIT dysmotility (OR 1.64, p = 0.004), and digital ulcers; pits; or digital amputation (OR 1.59, p = 0.014). Conclusions: GAVE is an underestimated and underappreciated SSc manifestation of SSc, which occurs with a relatively high frequency. Identifying an at-risk GAVE phenotype, as presented herein, is of practical importance as screening may prove advantageous given GAVE can be easily diagnosed and treated.


  • Risk‐adjusted hospital clinical management issue rates using data from the Victorian Audit of Surgical Mortality

    by Dylan Hansen, Claudia Retegan, Adam Ismail, Philip McCahy

    Background In recent years, there has been a concerted drive for an increase in public reporting of hospital‐level outcomes as a means of identifying strategies to improve patient safety. Surgical care, as a high‐risk area of medical practice, has come under sharp scrutiny. This study uses data from the Victorian Audit of Surgical Mortality (VASM) in conjunction with data from the Victorian Admitted Episode Dataset to compare hospital rates of clinically identified serious clinical management issues that were definitely or probably preventable and caused or contributed to the death of the patient who would otherwise be expected to survive. Methods Cases where the date of death was between 1 July 2015 and 30 June 2017 that completed the full VASM audit process were extracted from the VASM database and combined with data extracted from the Victorian Admitted Episode Dataset, where a surgical admission occurred in the same time period. A logistic regression model was used as a method of indirect standardization to derive the probability of preventable clinical management issues, which was then used to calculate the standardized incident rate for all Victorian surgical hospitals. Hospitals were compared by plotting the standardized incident rates on three funnel plots. Results There were five hospitals (8.3%) of the 60 that deviated significantly from the state‐wide rate of 0.00012. Conclusion The risk adjustment model identified several hospitals that may have a systematic issue which warrant further clinical quality assurance investigation.